DaVita (DVA) Q1 2026 earnings review
Guidance Upgrade Masked by IKC Volatility
DaVita delivered a robust start to 2026, beating expectations and raising full-year adjusted operating income and EPS guidance. The core narrative is positive: U.S. normalized treatment volume growth reversed from negative to positive (+0.1%) for the first time in over a year, and revenue grew 6% YoY. However, earnings quality shows mixed signals. While adjusted EPS surged 43.5% YoY to $2.87, much of this was engineered through aggressive share repurchases. Furthermore, the Integrated Kidney Care (IKC) segment swung back to an operating loss, contradicting the narrative of structural profitability established in late 2025.
🐂 Bull Case
After four consecutive quarters of decline, normalized non-acquired treatment growth reversed to +0.1%. The company is finally stabilizing its patient census.
Management confidently raised FY26 Adjusted Operating Income and EPS targets in the first quarter, signaling strong visibility into cost controls and commercial rate stability.
🐻 Bear Case
The IKC segment dropped back to a $19M operating loss, proving that the shift to value-based care remains economically lumpy and heavily dependent on shared savings timing.
Patient care costs per treatment hit $280.11, up 3.1% YoY, driven by wage inflation and insurance costs. DaVita remains highly exposed to labor market tightness.
⚖️ Verdict: 🟢
Bullish. The inflection in treatment volume growth is the most critical fundamental driver. When paired with upgraded guidance and relentless share repurchases, the financial trajectory is firmly upward, despite IKC lumpiness.
Key Themes
Volume Contraction is Reversing
The most significant operational update is that U.S. normalized non-acquired treatment growth reached +0.1% YoY, reversing a streak of negative growth (-0.6% in 25Q4, -0.6% in 25Q3). Management's long-term clinical initiatives to combat post-COVID mortality and missed treatments appear to be yielding tangible results.
IKC Profitability Reversing
In Q4 2025, management celebrated the first profitable year for Integrated Kidney Care (IKC) as validation of their value-based care strategy. However, 26Q1 data completely contradicts the narrative of stable profitability: the segment recorded a $19M operating loss. This massive sequential swing from a $46M profit in 25Q4 underscores severe timing and actuarial volatility in shared-savings recognition.
Aggressive Share Repurchases Compounding EPS
DaVita is buying back stock at a relentless pace. In 26Q1, the company repurchased 3.0M shares for $403M. Post-quarter, they bought an additional 2.0M shares for $302M. This reduction in the share float is the primary lever driving the 43.5% YoY growth in Adjusted EPS, acting as a massive financial driver independent of core dialysis operations.
Macro: ACA Subsidies and Commercial Mix
Management continues to navigate macro policy risks. The ongoing expiration of enhanced Affordable Care Act (ACA) premium tax credits remains a structural headwind (previously quantified at ~$40M for 2026). While the Q1 results absorbed this initial hit through rate increases, any further degradation in the commercial payer mix will directly pressure the bottom line.
Technology & Innovation Upgrades
Investments in AI-driven predictive scheduling and the rollout of next-gen clinical platforms are beginning to show structural benefits. DaVita Clinical Research's focus on High-Volume Hemodiafiltration (HDF) and middle-molecule clearance devices is acting as the backbone for reducing the elevated mortality rates that have plagued volume growth over the last two years.
Patient Care Cost Inflation
Patient care costs per treatment grew to $280.11 in Q1, up $8.34 YoY. Management cited increased compensation expenses and insurance costs. While revenue per treatment ($417.59) grew fast enough to cover this, the persistent wage inflation in clinical labor keeps operating leverage structurally constrained.
Other KPIs
Reversing positively from a $45 million outflow in the prior-year quarter. This is a critical metric, as trailing twelve-month FCF reached $1.2 billion, providing full coverage for the ongoing debt service and the aggressive stock buyback program.
Stable YoY. The segment matched 25Q1's $30 million operating income, maintaining its status as a steady, reliable contributor to enterprise growth, partially shielding the company from U.S. regulatory and labor market turbulence.
Guidance
Accelerating. Management raised the range from the previous $2,085 - $2,235 million. This reflects high confidence in cost controls and rate negotiations holding up through the year, despite the Q1 stumble in the IKC segment.
Accelerating. The midpoint of $14.65 represents a massive upgrade from the prior $14.30 midpoint. Driven almost entirely by the heavy concentration of share repurchases executed in Q1 and April/May.
Stable. Unchanged from prior guidance. The midpoint of $1.125 billion implies a slight step down from the trailing twelve-month generation of $1.209 billion, likely accounting for working capital timing.
Key Questions
IKC Volatility Drivers
IKC flipped from a $46M profit in Q4 to a $19M loss in Q1. How much of this variance is driven purely by the timing of retroactive shared-savings recognition versus actual deterioration in underlying medical cost management?
Volume Rebound Sustainability
Normalized treatment growth finally turned positive (+0.1%). Are we seeing the tangible benefits of specific clinical interventions (like HDF or vaccinations), or is this merely a mathematical stabilization of the post-COVID mortality baseline?
Share Repurchase ROI Thresholds
You repurchased shares post-quarter at an average price of nearly $150. As the multiple expands, how does your internal ROI calculation shift the balance between continued buybacks versus accelerating international M&A?